CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.76B, above the global median of $1.15B
- PositionReturn on equity is -1145.4%, lower than 95% of its Biotechnology peers (median -24.5%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.76BUSDvs all stocks (USD)
Revenue (TTM)
31.59MUSDvs all stocks (USD)
Beta
1.00xvs all stocks
52-Week Change
170.49%vs all stocks
Market Capitalization
1.76BUSDvs all stocks (USD)
Enterprise Value
1.81BUSDvs all stocks (USD)
Forward P/E
-22.50xvs Biotechnology peers
Price to Sales (TTM)
55.85xvs Biotechnology peers
Price to Book (MRQ)
86.84xvs Biotechnology peers
Enterprise to Revenue
57.18xvs Biotechnology peers
Enterprise to EBITDA
-20.93xvs Biotechnology peers
Gross Margin
88.99%vs Biotechnology peers
Operating Margin
-25.78%vs Biotechnology peers
Return on Assets (TTM)
-42.07%vs Biotechnology peers
Return on Equity (TTM)
-1145.42%vs Biotechnology peers
Revenue (TTM)
31.59MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0960USDUpdated Jul 19, 2026Quarterly Revenue Growth
1633.90%vs Biotechnology peers
Gross Profit (TTM)
-11.18MUSDvs all stocks (USD)
EBITDA (TTM)
-86.33MUSDvs all stocks (USD)
Net Income (TTM)
-383.42MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1633.93%vs Biotechnology peers
Operating Cash Flow (TTM)
-115.33MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-90.11MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
9.68MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
4.82MUSDFY2025 · Dec 31, 2025Gross Profit
4.86MUSDFY2025 · Dec 31, 2025Operating Income
-106.60MUSDvs all stocks (USD)
Pre-tax Income
-250.64MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.00KUSDFY2025 · Dec 31, 2025Net Income
-250.64MUSDFY2025 · Dec 31, 2025EBIT
-246.77MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-100.14MUSDFY2025 · Dec 31, 2025Research & Development
41.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
70.13MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.21MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.87MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.37USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.37USDFY2025 · Dec 31, 2025Basic Shares Outstanding
312.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
312.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-250.64MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-235.85MUSDFY2025 · Dec 31, 2025Free Cash Flow
-237.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
30.23MUSDFY2025 · Dec 31, 2025Income Tax Paid
3.00KUSDFY2025 · Dec 31, 2025Interest Paid
3.51MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-250.64MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.20MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
10.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
146.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.20MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
8.77MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.98MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-208.01MUSDFY2025 · Dec 31, 2025Sale of Investments
208.47MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.53MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
92.82MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-2.20MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.78MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
88.85MUSDFY2025 · Dec 31, 2025Shares Outstanding
355.90MSharesUpdated Jul 19, 2026Float Shares
189.66MSharesUpdated Jul 19, 2026Shares Short
44.22MSharesUpdated Jul 19, 2026Short Ratio
7.48daysvs all stocks
Short % of Shares Outstanding
22.83%vs all stocks
% Held by Insiders
13.71%vs all stocks
% Held by Institutions
71.19%vs all stocks
Total Cash (MRQ)
56.25MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.1580USDUpdated Jul 19, 2026Total Debt (MRQ)
98.25MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
4.86xvs Biotechnology peers
Current Ratio (MRQ)
4.82xvs Biotechnology peers
Book Value per Share (MRQ)
0.0570USDUpdated Jul 19, 2026Total Assets
155.50MUSDvs all stocks (USD)
Total Current Assets
115.23MUSDFY2025 · Dec 31, 2025Total Liabilities
134.59MUSDFY2025 · Dec 31, 2025Total Non-current Assets
40.27MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
97.29MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
30.23MUSDFY2025 · Dec 31, 2025Other Short-term Investments
67.62MUSDFY2025 · Dec 31, 2025Accounts Receivable
3.92MUSDFY2025 · Dec 31, 2025Inventory
9.58MUSDFY2025 · Dec 31, 2025Accounts Payable
11.98MUSDFY2025 · Dec 31, 2025Short-term Debt
1.14MUSDFY2025 · Dec 31, 2025Deferred Revenue
517.00KUSDFY2025 · Dec 31, 2025Long-term Debt
97.15MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
134.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-2.34BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
20.91MUSDvs all stocks (USD)
52-Week Low
1.47USDUpdated Jul 19, 202652-Week High
6.04USDUpdated Jul 19, 202652-Week Change
170.49%vs all stocks
Beta
1.00xvs all stocks
50-Day MA
4.68USDUpdated Jul 19, 2026200-Day MA
4.16USDUpdated Jul 19, 2026Avg 10-Day Volume
3.76MSharesUpdated Jul 19, 2026Avg 30-Day Volume
5.06MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.21USDUpdated Jul 19, 2026Other Income / Expense
-143.39MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -1145.4%, lower than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: -11.45Industry median: -0.25Industry P5: -1.55Peers compared: 197
Debt-to-equity is 4.86×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 4.86Industry median: 0.10Industry P95: 2.96Peers compared: 197
Price-to-book is 86.84×, higher than 95% of its Biotechnology peers (median 5.36×)Significant
Price-to-book: 86.84Industry median: 5.36Industry P95: 37.43Peers compared: 197
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 56,246,000Total Debt (USD): 98,250,000Debt-to-Equity: 4.86
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.76B, above the global median of $1.15BNotable
Market cap (USD): 1,764,729,351Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Shyndec Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Heron Neutron Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Harrow Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Ani Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule